Biosergen AS (BIOSGN) - Total Liabilities
Based on the latest financial reports, Biosergen AS (BIOSGN) has total liabilities worth Skr13.04 Million SEK (≈ $1.40 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore BIOSGN cash flow metrics to assess how effectively this company generates cash.
Biosergen AS - Total Liabilities Trend (2019–2025)
This chart illustrates how Biosergen AS's total liabilities have evolved over time, based on quarterly financial data. See what is Biosergen AS's book value for net asset value and shareholders' equity analysis.
Biosergen AS Competitors by Total Liabilities
The table below lists competitors of Biosergen AS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Odd Burger Corp
V:ODD
|
Canada | CA$6.70 Million |
|
Visionary Education Technology Holdings Group Inc.
NASDAQ:GV
|
USA | $58.43 Million |
|
TT Electronics Plc
LSE:TTG
|
UK | GBX284.20 Million |
|
DGB Asia Bhd
KLSE:0152
|
Malaysia | RM102.18 Million |
|
Onfolio Holdings Inc
NASDAQ:ONFO
|
USA | $4.55 Million |
|
NAYA Biosciences, Inc
NASDAQ:NAYA
|
USA | $33.70 Million |
|
CDN Maverick Capital Corp.
F:338B
|
Germany | €359.15K |
|
PolyPlank publ AB
ST:POLY
|
Sweden | Skr21.55 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Biosergen AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Biosergen AS (BIOSGN) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.61 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.62 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biosergen AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biosergen AS (2019–2025)
The table below shows the annual total liabilities of Biosergen AS from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr13.04 Million ≈ $1.40 Million |
+251.55% |
| 2024-12-31 | Skr3.71 Million ≈ $399.15K |
-27.06% |
| 2023-12-31 | Skr5.08 Million ≈ $547.23K |
-53.76% |
| 2022-12-31 | Skr11.00 Million ≈ $1.18 Million |
+18.84% |
| 2021-12-31 | Skr9.25 Million ≈ $995.77K |
-41.14% |
| 2020-12-31 | Skr15.72 Million ≈ $1.69 Million |
+38.26% |
| 2019-12-31 | Skr11.37 Million ≈ $1.22 Million |
-- |
About Biosergen AS
Biosergen AB (publ), a biotech company, develops antifungal products. Its lead product is BSG005, an antifungal drug candidate for the treatment of invasive fungal infections in immunocompromised patients, including AIDS, cancer, and transplant recipients. The company was founded in 2004 and is based in Solna, Sweden.